These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12124174)

  • 61. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
    Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
    Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The acidic microenvironment as a possible niche of dormant tumor cells.
    Peppicelli S; Andreucci E; Ruzzolini J; Laurenzana A; Margheri F; Fibbi G; Del Rosso M; Bianchini F; Calorini L
    Cell Mol Life Sci; 2017 Aug; 74(15):2761-2771. PubMed ID: 28331999
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis.
    Liu T; Liu D; Liu R; Jiang H; Yan G; Li W; Sun L; Zhang S; Liu Y; Guo K
    Sci Rep; 2017 Jan; 7():38918. PubMed ID: 28079114
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
    Hsu JL; Hung MC
    Cancer Metastasis Rev; 2016 Dec; 35(4):575-588. PubMed ID: 27913999
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adaptive Stress Responses During Tumor Metastasis and Dormancy.
    Senft D; Ronai ZE
    Trends Cancer; 2016 Aug; 2(8):429-442. PubMed ID: 27868104
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Docosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKCδ- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.
    Lian S; Xia Y; Nguyen TT; Ung TT; Yoon HJ; Kim NH; Kim KK; Jung YD
    PLoS One; 2016; 11(9):e0163395. PubMed ID: 27654969
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
    Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
    Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
    Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
    [TBL] [Abstract][Full Text] [Related]  

  • 69. uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
    Tarighi P; Montazeri H; Khorramizadeh MR; Sobhani AM; Ostad SN; Ghahremani MH
    Res Pharm Sci; 2015; 10(3):200-5. PubMed ID: 26600846
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.
    Kim KK; Han A; Yano N; Ribeiro JR; Lokich E; Singh RK; Moore RG
    Sci Rep; 2015 Nov; 5():15911. PubMed ID: 26568478
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Integrin α5 Suppresses the Phosphorylation of Epidermal Growth Factor Receptor and Its Cellular Signaling of Cell Proliferation via N-Glycosylation.
    Hang Q; Isaji T; Hou S; Im S; Fukuda T; Gu J
    J Biol Chem; 2015 Dec; 290(49):29345-60. PubMed ID: 26483551
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Urokinase receptor and resistance to targeted anticancer agents.
    Gonias SL; Hu J
    Front Pharmacol; 2015; 6():154. PubMed ID: 26283964
    [TBL] [Abstract][Full Text] [Related]  

  • 73. EGFR Amplification and Glioblastoma Stem-Like Cells.
    Liffers K; Lamszus K; Schulte A
    Stem Cells Int; 2015; 2015():427518. PubMed ID: 26136784
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.
    Longo A; Librizzi M; Chuckowree IS; Baltus CB; Spencer J; Luparello C
    Molecules; 2015 May; 20(6):9879-89. PubMed ID: 26029857
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhanced Therapeutic Epidermal Growth Factor Receptor (EGFR) Antibody Delivery via Pulsed Ultrasound with Targeting Microbubbles for Glioma Treatment.
    Liao AH; Chou HY; Hsieh YL; Hsu SC; Wei KC; Liu HL
    J Med Biol Eng; 2015; 35(2):156-164. PubMed ID: 25960704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Human sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.
    Mekkawy AH; Morris DL
    ISRN Biochem; 2013; 2013():598251. PubMed ID: 25937961
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
    Indira Chandran V; Eppenberger-Castori S; Venkatesh T; Vine KL; Ranson M
    Oncoscience; 2015; 2(3):207-24. PubMed ID: 25897424
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
    J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.
    Sosa MS; Parikh F; Maia AG; Estrada Y; Bosch A; Bragado P; Ekpin E; George A; Zheng Y; Lam HM; Morrissey C; Chung CY; Farias EF; Bernstein E; Aguirre-Ghiso JA
    Nat Commun; 2015 Jan; 6():6170. PubMed ID: 25636082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.